PierluigiPorcuMD
Oncology • Philadelphia, PAHematologic Oncology
Professor of Medical Oncology, Division Director of Hematologic Malignancies, and IRT Program Leader, Sidney Kimmel Cancer Center at Jefferson
Dr. Porcu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
925 Chestnut St
Ste 420A
Philadelphia, PA 19107Phone+1 215-955-8874Fax+1 215-955-2340- Is this information wrong?
Summary
- Dr. Pierluigi Porcu is a medical oncologist and physician scientist with a research focus in T-cell and NK-cell lymphoma and EBV-associated lymphomas. He is Division Director, Heme Malignancies and Hematopoietic Stem Cell transplantation and Program Leader, Immune Cell Regulation and Targeting at the Sidney Kimmel Cancer Center at Thomas Jefferson University, in Philadelphia, PA. He received his medical degree from University of Torino Faculty of Medicine and has been in academic practice in the US more than 20 years. He specializes in T-cell and NK-cell lymphomas and is an expert in the development of new therapies for blood cancers.
Education & Training
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1999- Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
University of Torino Faculty of MedicineClass of 1987
Certifications & Licensure
NJ State Medical License 2019 - 2025
PA State Medical License 2016 - 2024
OH State Medical License 1999 - 2018
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer Start of enrollment: 2000 Dec 01
- Open Label Study of ONTAK (Denileukin Diftitox, DAB389 IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Start of enrollment: 2004 Nov 01
- CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma.Laura Gleason, Ladan Afifi, Lauren Banner, Sahithi Talasila, Daniel Joffe, Onder Alpdogan, Safiyyah Bhatti, Pierluigi Porcu, Neda Nikbakht> ;Molecular and Clinical Oncology. 2024 May 1
- Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A SEER database analysis.Lauren Banner, Thomas Z Rohan, Tyler Gross, Henry Y Yang, Daniel Joffe, Rachel Zachian, Pierluigi Porcu, Neda Nikbakht> ;Journal of the American Academy of Dermatology. 2024 Mar 19
- Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.Davila, E., Bradeen, X., Abbott, D., Zain, J., Kamdar, M., Neuwelt, A., Jasem, J., Porcu, P., Major, A., Major, A., Haverkos, B., Major, A., Bair, S., Smith, C.> ;Blood Advances. 2024 Feb 13
- Join now to see all
Journal Articles
- Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORICPierluigi Porcu, MD, European Journal of Cancer
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyMichael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
- IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 StudyPierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer
Abstracts/Posters
- Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ...Pierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Prospective Cohort of Black Patients with Mycosis Fungoides and S_zary Syndrome: Subset Analysis of the Mavoric TrialPierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.2019 ASCO Annual Meeting - 6/1/2019
- Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicul...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Long-Term Efficacy and Safety from the Copanlisib CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- SOHO 2021: A Rapidly Changing Treatment Landscape in Classical Hodgkin’s LymphomaSeptember 2021
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018
- Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORICAugust 2018
- IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 StudyAugust 2018
- Join now to see all
Press Mentions
Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of Its Recent End of Phase 2 Meeting with the FDADecember 7th, 2020
Viracta Announces Oral Presentation on Lead Program for EBV-Associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual MeetingNovember 6th, 2019
Treatment Delays with CAR-T Therapy: A High Price to PaySeptember 11th, 2019- Join now to see all
Professional Memberships
- Member
- Chair, ASH Foundation Committee
- Member
Other Languages
- Italian
External Links
- LinkedInhttps://www.linkedin.com/in/pierluigi-porcu-661b9040?trk=nav_responsive_tab_profile_pic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
